Levy S B, Marshall B, Rowse-Eagle D, Onderdonk A
Science. 1980 Jul 18;209(4454):391-4. doi: 10.1126/science.6992276.
Survival in the mouse and human intestine of Escherichia coli host-vector systems used and proposed for recombinant DNA technology was assessed. There was no detectable survival of severely disabled E. coli K12 strain X1776 in mice or in human subjects 24 hours after ingestion. The same strain bearing the plasmid pBR322, however, was recovered from human subjects for 4 days in amounts of six organisms for every million ingested. Nondisabled E. coli K12 strain X1666, with or without pBR322, survived in 10(4)-fold greater numbers and for 2 days longer, with better recovery of the plasmid-containing derivative. Although the plasmid-bearing strains were recovered for longer periods, no intestinal colonization was noted. Despite the presence of pBR322 for a maximum of 6 days in the human intestine, there was no evidence that it was transferred from either bacterial host to endogenous aerobic fecal bacteria.
对用于重组DNA技术以及提议使用的大肠杆菌宿主载体系统在小鼠和人类肠道中的存活情况进行了评估。摄入后24小时，严重致残的大肠杆菌K12菌株X1776在小鼠或人类受试者体内均未检测到存活情况。然而，携带质粒pBR322的同一菌株在人类受试者体内可被检出长达4天，每摄入一百万个该菌株，可回收六个菌株。未致残的大肠杆菌K12菌株X1666，无论有无pBR322，存活数量都多10⁴倍，存活时间长2天，含质粒衍生物的回收率更高。尽管携带质粒的菌株回收时间更长，但未观察到肠道定植现象。尽管pBR322在人类肠道中最多存在6天，但没有证据表明它从任何一种细菌宿主转移到内源性需氧粪便细菌中。
